Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
CHESTERBROOK, Pa., March 14, 2018 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the Oppenheimer & Company 28th Annual Healthcare Conference on Wednesday, March 21, 2018, at 2:45 p.m. EDT in New York, NY.
To join a live audio webcast of the presentation, please visit the Investor section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on providing better, safer therapies to patients in pain. The Company has leveraged breakthrough science to discover and develop its investigational product OLINVO™ (oliceridine) Injection for the management of moderate-to-severe acute pain. OLINVO has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration, and is intended to provide healthcare providers an innovative new option for patients who require an intravenous opioid. The Company also has an early stage pipeline of new chemical entities targeting novel mechanisms of action, including TRV250 for acute migraine, neuropathic pain, and other indications.
Contacts
Trevena, Inc.
Investors:
Jonathan Violin, Ph.D.
Senior Vice President, Scientific Affairs & Investor Relations Officer
610-354-8840 x231
[email protected]
or
Media:
Public Relations
[email protected]
